Malaria Vaccines: Pfs25-rEPA and Pfs230-rEPA — Patrick Duffy (NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES)
The major challenge facing TBV development is to find a highly safe formulation that induces sustained high antibody responses. LMIV has demonstrated that conjugating Pfs25 and Pfs230 with carrier pro
| Project title | Malaria Vaccines: Pfs25-rEPA and Pfs230-rEPA |
|---|---|
| Project number | 1ZIAAI001009-15 |
| PI name | Patrick Duffy |
| Institution | NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES |
| Funding mechanism | ZIA |
| Agency | NIAID |
| Award amount | $6.43M |
| Fiscal year | 2021 |
| Abstract | The major challenge facing TBV development is to find a highly safe formulation that induces sustained high antibody responses. LMIV has demonstrated that conjugating Pfs25 and Pfs230 with carrier pro |
| Key terms | <0-11 years old><21+ years old><Adjuvant><Adult><Adult Human><Age><Alhydrogel><Alum Adjuvant><Anti-M |
$799/mo
Try GrantRadar →